Stephanie Murphy
Family · Kansas City, KSNPI 1568957249
Payments from drug & device makers
Across 87 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$375
- Astellas Pharma US Inc$290
- Lilly USA, LLC$255
- Amgen$79
- Novo Nordisk$64
- AstraZeneca$52
- plus $361 from 13 others
What the payments were for
- Food & beverage$1,475100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $375 |
| Astellas Pharma US Inc | 12 | $290 |
| Lilly USA, LLC | 14 | $255 |
| Amgen | 5 | $79 |
| Novo Nordisk | 4 | $64 |
| AstraZeneca | 3 | $52 |
| Organon | 4 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Nevro Corp. | 2 | $35 |
| Boston Scientific | 2 | $32 |
| Merck | 2 | $32 |
| Corium, LLC | 4 | $31 |
| Pfizer | 2 | $30 |
| Vertex | 1 | $26 |
| Phadia US Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Bayer | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
How this compares
$1,475 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $65,142 |
| TrulicityDulaglutide | 26 | $40,388 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $33,095 |
| JardianceEmpagliflozin | 20 | $20,076 |
| MounjaroTirzepatide | 14 | $14,687 |
| EliquisApixaban | 11 | $10,349 |
| JanuviaSitagliptin Phosphate | 12 | $10,160 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $4,956 |
| Duloxetine Hcl | 160 | $3,454 |
| Celecoxib | 83 | $2,971 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,857 |
| Atorvastatin Calcium | 273 | $2,542 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,255 |
| Gabapentin | 140 | $2,122 |
| Zonisamide | 12 | $1,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $64 | $65,14252 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $255 | $55,07540 claims |
| Boehringer IngelheimJardiance | $14 | $20,07620 claims |
| PfizerEliquis | $30 | $10,34911 claims |
| MerckJanuvia | $32 | $10,16012 claims |
| AbbVieSynthroid | $375 | $92412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.
Other family in Kansas City
- Zohra HussainiKansas City$329K
- Adam CaseKansas City$34K
- Kristina DelaneyKansas City$27K
- Amanda WilliamsKansas City$20K
- Mindy EldridgeKansas City$12K
- Liza RodriguezKansas City$11K
- Jhunne GalimbaKansas City$6K
- Graceann SandriKansas City$6K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.